Patents Assigned to Supratek Pharma, Inc.
-
Patent number: 8703964Abstract: The present invention is directed to pharmaceutical compositions comprising: (a) bendamustine, (b) a charged cyclopolysaccharide, and (c) a stabilizing agent having a charge opposite to that of the cyclopolysaccharide. Such composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. Such compositions are suitable for injection or infusion into patients in need for treatment with bendamustine.Type: GrantFiled: March 11, 2013Date of Patent: April 22, 2014Assignee: Supratek Pharma Inc.Inventors: Tomasz Popek, Kishore Patel, Valery Alakhov, Grzegorz Pietrzynski
-
Publication number: 20130190372Abstract: The present invention is directed to pharmaceutical compositions comprising: (a) bendamustine, (b) a charged cyclopolysaccharide, and (c) a stabilizing agent having a charge opposite to that of the cyclopolysaccharide. Such composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. Such compositions are suitable for injection or infusion into patients in need for treatment with bendamustine.Type: ApplicationFiled: March 11, 2013Publication date: July 25, 2013Applicant: SUPRATEK PHARMA INC.Inventor: SUPRATEK PHARMA INC.
-
Patent number: 8436032Abstract: The present invention is directed to pharmaceutical compositions comprising: (a) bendamustine, (b) a charged cyclopolysaccharide, and (c) a stabilizing agent having a charge opposite to that of the cyclopolysaccharide. Such composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. Such compositions are suitable for injection or infusion into patients in need for treatment with bendamustine.Type: GrantFiled: February 24, 2010Date of Patent: May 7, 2013Assignee: Supratek Pharma Inc.Inventors: Tomasz Popek, Kishore Patel, Valery Alakhov, Grzegorz Pietrzynski
-
Patent number: 8389558Abstract: The present invention is directed to pharmaceutical compositions comprising bendamustine and one or more amphiphilic anionic compounds and self assembled aggregates, which aggregates exhibit enhanced stability in aqueous solutions, including plasma, are disclosed. The unexpectedly enhanced stability afforded by such aggregates permits patients to be treated with bendamustine in lower and/or with less frequent dosages or to improve its therapeutic effect while using the same as presently used treatment protocol.Type: GrantFiled: July 19, 2010Date of Patent: March 5, 2013Assignee: Supratek Pharma Inc.Inventors: Valery Alakhov, Grzegroz Pietrzynski, Patel Kishore, Thomasz Popek
-
Patent number: 8383663Abstract: The present invention is directed to pharmaceutical compositions including: (a) bendamustine, (b) a first charged cyclopolysaccharide, and (c) a stabilizing agent which is a second charged cyclopolysaccharide having a charge opposite to that of the first charged cyclopolysaccharide. The composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. The compositions are suitable for injection or infusion into patients in need for treatment with bendamustine.Type: GrantFiled: February 22, 2011Date of Patent: February 26, 2013Assignee: Supratek Pharma Inc.Inventors: Valery Alakhov, Grzegorz Pietrzynski, Patel Kishore, Thomasz Popek
-
Patent number: 8148338Abstract: Doxorubicin block copolymer formulations for use in preparing injectable compositions for treating cancer patients which contain lactose for solubilizing the doxorubicin and block copolymers in said formulations and methyl paraben for stabilizing these formulations, as well as a method of preparing and using these injectable compositions.Type: GrantFiled: February 22, 2006Date of Patent: April 3, 2012Assignee: Supratek Pharma Inc.Inventors: Evgueni Klinski, Kishore Patel, Grzegorz Pietrzynski, Valery Alakhov
-
Patent number: 7772255Abstract: The use of azaxanthones for treating diseases associated with tumor cells which express one or more protein of S100 family, and in treating patients that have malignancies consisting of tumors of an epithelial or mesenchymel nature, where these compounds are effective in retarding the progression and/or metastasis of these tumors.Type: GrantFiled: December 13, 2005Date of Patent: August 10, 2010Assignee: Supratek Pharma, Inc.Inventors: Alexandre Semov, Grzegorz Pietrzynski, Valery Alakhov
-
Publication number: 20080003288Abstract: A responsive microgel is provided which responds volumetrically and reversibly to a change in one or more aqueous conditions selected from the group consisting of (temperature, pH, and ionic conditions) comprised of an ionizable network of covalently cross-linked homopolymeric ionizable monomers wherein the ionizable network is covalently attached to an amphiphilic copolymer to form a plurality of ‘dangling chains’ and wherein the ‘dangling chains’ of amphiphilic copolymer form immobile micelle-like aggregates in aqueous solution. A responsive microgel is further provided that comprises at least one therapeutic entity and delivers a substantially linear and sustained release of the therapeutic entity under physiological conditions.Type: ApplicationFiled: April 11, 2007Publication date: January 3, 2008Applicant: Supratek Pharma Inc.Inventors: Lev Bromberg, Marina Temchenko
-
Patent number: 7256180Abstract: Compositions induce the activation of dendritic cells comprising a polynucleotide, such as viruses, RNA, DNA, plasmid DNA, or derivatives thereof and at least one block copolymer of alkylethers. The present invention further relates to compositions for inducing the activation of dendritic cells wherein the block copolymers are PLURONIC F127 and L61. More particular, the compositions comprise block copolymers PLURONIC F127/PLURONIC L61. The invention also relates to methods of inducing the activation of dendritic cells in animals comprising administering the compositions of the invention. Additionally, the present invention relates to methods of increasing the immune response of animals comprising administering the compositions of the present invention.Type: GrantFiled: April 30, 2001Date of Patent: August 14, 2007Assignee: Supratek Pharma Inc.Inventors: Alexander V. Kabanov, Pierre Lemieux, Valery Alakhov, Nadia Guerin
-
Patent number: 7204997Abstract: A responsive microgel is provided which responds volumetrically and reversibly to a change in one or more aqueous conditions selected from the group consisting of (temperature, pH, and ionic conditions) comprised of an ionizable network of covalently cross-linked homopolymeric ionizable monomers wherein the ionizable network is covalently attached to an amphiphilic copolymer to form a plurality of ‘dangling chains’ and wherein the ‘dangling chains’ of amphiphilic copolymer form immobile micelle-like aggregates in aqueous solution. A responsive microgel is further provided that comprises at least one therapeutic entity and delivers a substantially linear and sustained release of the therapeutic entity under physiological conditions.Type: GrantFiled: November 18, 2002Date of Patent: April 17, 2007Assignee: Supratek Pharma Inc.Inventors: Lev E. Bromberg, Marina Temchenko
-
Patent number: 7112654Abstract: The present invention relates to compositions comprised of a peptide ligand or derivatives thereof that are capable of specific binding to the high affinity receptor-1 of vascular endothelial growth factor (VEGF) and structure similar receptors. The invention further provides a peptide ligand or derivatives thereof that are capable of inhibiting angiogenesis induced by VEGF. The present invention also provides a method for treatment or diagnosis of disease associated with angiogenesis in a patient in need of therapy comprising administering to the patient an effective amount of the pharmaceutical composition of the present invention and a pharmaceutical acceptable carrier.Type: GrantFiled: February 23, 2004Date of Patent: September 26, 2006Assignee: Supratek Pharma Inc.Inventors: Lioudmila Tchistiakova, Shengmin Li, Grzegorz Pietrzynski, Valery Alakhov
-
Patent number: 6733755Abstract: The present invention relates to compositions comprised of a peptide ligand or derivatives thereof that are capable of specific binding to the high affinity receptor-1 of vascular endothelial growth factor (VEGF) and structure similar receptors. The invention further provides a peptide ligand or derivatives thereof that are capable of inhibiting angiogenesis induced by VEGF. The present invention also provides a method for treatment or diagnosis of disease associated with angiogenesis in a patient in need of therapy comprising administering to the patient an effective amount of the pharmaceutical composition of the present invention and a pharmaceutical acceptable carrier.Type: GrantFiled: February 2, 2001Date of Patent: May 11, 2004Assignee: Supratek Pharma, Inc.Inventors: Lioudmila Tchistiakova, Shengmin Li, Grzegorz Pietrzynski, Valery Alakhov
-
Patent number: 6696274Abstract: Provided herein is a novel and useful Ligand comprising a peptide comprising an amino acid sequence of SEQ. ID. NO.:6, an analog, a derivative, or a variant thereof, which increases the absorption of biological agents across the blood brain barrier and the gastrointestinal barrier. As a result, a Ligand of the present invention increases the bioavailability of biological agents administered orally.Type: GrantFiled: May 3, 2001Date of Patent: February 24, 2004Assignee: Supratek Pharma, Inc.Inventors: Lioudmila Tchistiakova, Shengmin Li, Grzegorz Pietrzynski, Valery Alakhov
-
Patent number: 6656459Abstract: Compositions comprising non-ionic block copolymers are useful for the treatment of autoimmune, inflammatory and proliferative diseases and for reducing graft/implantation rejection. The present invention also relates to methods of treating animals having various autoimmune, inflammatory and proliferative diseases. The present invention also relates to methods of reducing inflammation in an animal comprising administering the compositions of the invention. Also, the present invention relates to methods of reducing autoimmune responses and to methods of reducing graft/implantation rejection comprising administering the compositions of the inventions. A typical embodiment is a mixture of Pluronics F127 and L61.Type: GrantFiled: May 10, 2001Date of Patent: December 2, 2003Assignee: Supratek Pharma Inc.Inventors: Alexander V. Kabanov, Pierre Lemieux, Nadia Guerin, Valery Alakhov
-
Patent number: 6440743Abstract: Compositions for stabilizing polynucleic acids and increasing the ability of polynucleic acids to cross cell membranes and act in the interior of a cell. In one aspect, the invention provides a polynucleotide complex between a polynucleotide and certain polyether block copolymers. The polynucleotide complex can further include a polycationic polymer, as well as suitable targeting molecules and surfactants. The invention also provides a polynucleotide complex between a polynucleotide and a block copolymer comprising a polyether block and a polycation block.Type: GrantFiled: May 26, 1999Date of Patent: August 27, 2002Assignee: Supratek Pharma Inc.Inventors: Alexander V. Kabanov, Valery Y. Alakov, Serguie Vinogradov
-
Patent number: 6387406Abstract: Compositions for oral delivery having a biological agent or protein, peptide, or derivative thereof, and a poly(oxyethylene)-poly(oxypropylene) block copolymer. The compositions are useful in oral delivery of numerous agents. The invention also encompasses methods of treatment using the same.Type: GrantFiled: July 17, 2001Date of Patent: May 14, 2002Assignee: Supratek Pharma Inc.Inventors: Alexander V. Kabanov, Valery Y. Alakhov, Elena V. Batrakova
-
Patent number: 6387633Abstract: The present invention provides a method for the generation and identification cell lines that posses genetically unstable genes. More specifically, the present invention provides a method for detecting genes associated in genetic alterations by using specific genes capable of inducing genetic instability such as metastasin 1 gene and their protein products.Type: GrantFiled: May 11, 2001Date of Patent: May 14, 2002Assignee: Supratek Pharma, Inc.Inventor: Anatoli Onichtchenko
-
Patent number: 6359054Abstract: Compositions and methods for intramuscular administration of polynucleotides, such as RNA, DNA, or derivatives thereof comprising polynucleotides and block copolymers of alkylethers. The invention also provides compositions and methods for stabilizing polynucleic acids and increasing the ability of polynucleic acids to cross cell membranes and act in the interior of a cell.Type: GrantFiled: January 8, 1999Date of Patent: March 19, 2002Assignee: Supratek Pharma Inc.Inventors: Pierre M. Lemieux, Alexander V. Kabanov, Valery Y. Alakov, Sergey V. Vinogradov
-
Patent number: 6353055Abstract: The invention provides compositions for stabilizing polynucleic acids and increasing the ability of polynucleic acids to cross cell membranes and act in the interior of a cell. In one aspect, the invention provides a polynucleotide complex between a polynucleotide and certain polyether block copolymers. Preferably, the polynucleotide complex will further include a polycationic polymer. The compositions can further include suitable targeting molecules and surfactants. In another aspect, the invention provides a polynucleotide complex between a polynucleotide and a block copolymer comprising a polyether block and a polycation block. In yet another aspect, the invention provides polynucleotides 10 that have been covalently modified at their 5′ or 3′ end to attach a polyether polymer segment.Type: GrantFiled: August 1, 1997Date of Patent: March 5, 2002Assignee: Supratek Pharma Inc.Inventors: Alexander Victorovich Kabanov, Valery Yulievich Alakov, Sergey V. Vingogradov
-
Patent number: 6333051Abstract: Copolymer networks having at least one cross-linked polyamine polymer fragment and at least one nonionic water-soluble polymer fragment, and compositions thereof, having at least one suitable biological agent.Type: GrantFiled: September 3, 1998Date of Patent: December 25, 2001Assignee: Supratek Pharma, Inc.Inventors: Alexander V. Kabanov, Sergey V. Vinogradov